NCT03367819
Clinical Trial Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03367819
Title Isatuximab in Combination With REGN2810 in Patients With Advanced Malignancies
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Sanofi
Indications
lung non-small cell carcinoma
prostate cancer
Therapies
Isatuximab
Cemiplimab + Isatuximab
Age Groups: adult | senior
Covered Countries USA | ITA | GBR | FRA

Facility Status City State Zip Country Details
Investigational Site Number 8400003 Birmingham Alabama 35249 United States Details
Investigational Site Number 8400007 Atlanta Georgia 30322 United States Details
Investigational Site Number 8400002 Hackensack New Jersey 07601 United States Details
Investigational Site Number 8400005 Nashville Tennessee 37203 United States Details
Investigational Site Number 8400004 Houston Texas 77030 United States Details
Investigational Site Number 2500002 Bordeaux 33076 France Details
Investigational Site Number 2500001 Villejuif 94800 France Details
Investigational Site Number 3800003 Rozzano Milano 20089 Italy Details
Investigational Site Number 3800001 Orbassano Torino 10043 Italy Details
Investigational Site Number 3800006 Napoli 80131 Italy Details
Investigational Site Number 3800004 Padua 35128 Italy Details
Investigational Site Number 3800005 Verona 37134 Italy Details
Investigational Site Number 1580002 Tainan 704 Taiwan Details
Investigational Site Number 1580001 Taipei Taiwan Details
Investigational Site Number 8260001 Sutton Surrey SM2 5PT United Kingdom Details
Investigational Site Number 8260002 Newcastle upon Tyne NE7 7DN United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field